In addition to β-cell dysfunction, the absence of incretins is now recognized as one of the significant contributors to the development of T2DM [10]. Consequently, GLP-1 receptor agonists have emerged as a promising therapeutic option for managing diabetes. This evidence concerns the gene GLP1R and diabetes mellitus.